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Abstract
Background: Lung ischemia-reperfusion injury (LIRI) is suggested to be a major risk factor for
development of primary acute graft failure (PAGF) following lung transplantation, although other
factors have been found to interplay with LIRI. The question whether LIRI exclusively results in
PAGF seems difficult to answer, which is partly due to the lack of a long-term experimental LIRI
model, in which PAGF changes can be studied. In addition, the long-term effects of LIRI are unclear
and a detailed description of the immunological changes over time after LIRI is missing. Therefore
our purpose was to establish a long-term experimental model of LIRI, and to study the impact of
LIRI on the development of PAGF, using a broad spectrum of LIRI parameters including leukocyte
kinetics.
Methods: Male Sprague-Dawley rats (n = 135) were subjected to 120 minutes of left lung warm
ischemia or were sham-operated. A third group served as healthy controls. Animals were sacrificed
1, 3, 7, 30 or 90 days after surgery. Blood gas values, lung compliance, surfactant conversion,
capillary permeability, and the presence of MMP-2 and MMP-9 in broncho-alveolar-lavage fluid
(BALf) were determined. Infiltration of granulocytes, macrophages and lymphocyte subsets
(CD45RA+, CD5+CD4+, CD5+CD8+) was measured by flowcytometry in BALf, lung parenchyma,
thoracic lymph nodes and spleen. Histological analysis was performed on HE sections.
Results:  LIRI resulted in hypoxemia, impaired left lung compliance, increased capillary
permeability, surfactant conversion, and an increase in MMP-2 and MMP-9. In the BALf, most
granulocytes were found on day 1 and CD5+CD4+ and CD5+CD8+-cells were elevated on day 3.
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Increased numbers of macrophages were found on days 1, 3, 7 and 90. Histology on day 1 showed
diffuse alveolar damage, resulting in fibroproliferative changes up to 90 days after LIRI.
Conclusion: The short-, and long-term changes after LIRI in this model are similar to the changes
found in both PAGF and ARDS after clinical lung transplantation. LIRI seems an independent risk
factor for the development of PAGF and resulted in progressive deterioration of lung function and
architecture, leading to extensive immunopathological and functional abnormalities up to 3 months
after reperfusion.
Background
Lung transplantation is currently an accepted treatment
option for patients with end-stage pulmonary diseases,
even though the outcome remains limited [1]. Develop-
ment of primary acute graft failure (PAGF) occurs in
15–30% of lung transplant recipients and is the main
cause for early morbidity and mortality after lung trans-
plantation, resulting in a one-year survival rate of approx-
imately 80% [1-3]. Lung ischemia reperfusion injury
(LIRI) has been suggested to be a major risk factor for
PAGF, although other factors like donor brain death,
mechanical ventilation, pneumonia, hypotension, aspira-
tion, donor trauma and allo-immunity have been found
to interplay with LIRI in PAGF development [1-4]. The
clinical expression of LIRI may range from mild hypox-
emia and mild pulmonary edema on chest X-ray to PAGF,
which is the most severe form of injury [1]. Symptoms of
PAGF usually develop within 72 hours after reperfusion
and consist of hypoxemia, which cannot be corrected by
supplemental oxygen, non-cardiogenic pulmonary
edema, increased pulmonary artery pressure, and
decreased lung compliance [1,3-5].
Even though a positive correlation between cold ischemia
time and PAGF development has been suggested [3,6-8],
other studies found that duration of cold ischemia did not
predict outcome after lung transplantation and suggested
that other factors interplay with LIRI in PAGF develop-
ment [9-14]. The question whether LIRI is an independent
risk factor for the development of PAGF seems difficult to
answer. In clinical studies, often multiple interfering fac-
tors are examined simultaneously. Furthermore, a long-
term experimental LIRI model, in which PAGF changes
can be studied, is missing. The majority of experimental
studies use ex vivo LIRI models, like the Langendorff sys-
tem, which is a non-physiological model and in which it
is impossible to investigate reperfusion times beyond the
first hours. In addition, an experimental lung transplanta-
tion model with the induction of cold ischemia is techni-
cally difficult in rodents. Thus, the purpose of this study
was to establish an in vivo model of unilateral severe LIRI
and to determine whether symptoms resembling PAGF
after clinical lung transplantation could be induced.
Although the use of warm rather than cold ischemia
seems controversial, it has been demonstrated that there
are no major differences between short periods of warm
and longer periods of cold ischemia [15]. Moreover, warm
ischemia has been used extensively in IRI models of liver
and kidney as an accelerated model of clinically relevant
cold IRI [16-19].
Since most studies have only investigated the early hours
of reperfusion [19-32], the effect of severe LIRI up to
months after reperfusion is unknown. Furthermore a
detailed description of the subset of leukocytes and the
time course of infiltration on both short and long term
after LIRI is currently missing. Therefore, we have investi-
gated a broad spectrum of LIRI parameters, including lung
function, capillary permeability, matrix metallo protein-
ase (MMP) production, surfactant conversion, and histo-
logical changes on the short (days) and long-term
(months) after LIRI and we have described leukocyte
kinetics.
Finally, in the case of single lung transplantation, the
changes in the native lung after transplantation of the con-
tralateral side are not well established, especially on the
long term. Therefore, we also assessed changes in non-
ischemic right lung in animals undergoing left-sided LIRI.
Methods
Experimental design
The experimental protocol was approved by the Animal
Experiments Committee under the Dutch National Exper-
iments on Animals Act and complied with the 1986 direc-
tive 86/609/EC of the Council of Europe. Male Sprague-
Dawley rats (n = 135, weighing 295 ± 4 grams) (Harlan,
The Netherlands) were randomised into the experimental
LIRI (n = 75), sham-operated (n = 50) or unoperated (n =
10) group. LIRI (n = 15 per time point) and sham-oper-
ated (n = 10 per time point) animals were killed on day 1,
3, 7, 30 or 90 postoperatively. Animals in the LIRI group
were subjected to 120 minutes of warm ischemia of the
left lung. Sham-operated animals underwent the same
protocol as LIRI animals without applying left lung
ischemia; unoperated controls were killed without any
intervention.Respiratory Research 2008, 9:28 http://respiratory-research.com/content/9/1/28
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Surgical procedure
Animals were anesthetized with 60 mg/kg of ketaminhy-
drochloride intraperitoneally and a gas mixture (1.5–3%
isoflurane, 57% NO2 and 40% O2), whereafter they were
intubated and pressure control ventilated on a Siemens
Servo 900C ventilator (Maquet Critical Care AB, Solna,
Sweden) (14 cm H2O peak inspiratory pressure (PIP), 4
cm H2O positive end expiratory pressure (PEEP), fre-
quency 40 breaths/minute, fraction of inspired oxygen
(FiO2) 0.4). Following a left dorsolateral thoracotomy in
the fourth intercostal space, the inferior pulmonary liga-
ment was divided. The left lung was mobilized atraumat-
ically, and lung ischemia was induced by clamping the
bronchus, pulmonary artery and vein of the left inflated
lung using a single noncrushing microvascular clamp. At
reperfusion, the lung was recruited by a stepwise increase
of PIP and PEEP (maximum respectively 50 and 18 cm
H2O) until the lung was visually expanded. Recruitment
was also performed in sham-operated animals. The thorax
was closed and the animals received 5 ml of 5% glucose
intraperitoneally and 0.1 mg/kg of buprenorphinhydro-
chloride (0.3 mg/ml) intramuscularly and were weaned
from the ventilator. Body temperature was kept within
normal range with a heating pad. All animals recovered
with additional oxygen during the first 12 hours.
Blood gas values
At the end of the experiment (at day 1, 3, 7, 30 or 90), ani-
mals were anesthetized with 20 mg/kg intraperitoneally
administered pentobarbital (60 mg/ml) and a gas mixture
(3% isoflurane, 64% NO2 and 33% O2). After weighing
the animals, a polyethylene catheter (0.8 mm outer diam-
eter) was inserted into the carotid artery and a metal can-
nula was inserted into the trachea. Thereafter, anesthesia
was continued with 20 mg/kg pentobarbital intraperito-
neally and 0.7 mg/kg pancuronium bromide (2 mg/ml)
intramuscularly, whereafter animals were ventilated for 5
minutes (12 cm H2O PIP, 2 cm H2O PEEP, frequency 30
breaths/minute and FiO2 1.00). Blood gas values were
recorded in 0.3 ml heparinized blood taken from the
carotid artery (ABL555 gas analyzer, Radiometer, Copen-
hagen, Denmark). Animals were exsanguinated and euth-
anised by an overdose of pentobarbital (200 mg/kg),
administered intravenously.
Static compliance
The thorax and diaphragm were opened to eliminate the
influence of chest wall compliance and abdominal pres-
sure and a static pressure-volume curve (PVC) of the left
and right lung together and left lung separately was
recorded as described previously [33]. The PVC of the
individual left lung was conducted by clamping the con-
tralateral hilum. Maximal compliance (Cmax) was deter-
mined as the steepest part of the lung deflation curve.
Maximal lung volume (Vmax), corrected for body weight,
was recorded at a pressure of 35 cm H2O.
Broncho-alveolar lavage
Left and right lung were lavaged separately five times with
5 ml sodium chloride containing 1.5 mM CaCl2. Total
recovered volume of BALf was noted. Cell suspensions
were centrifuged at 400 g and 4°C for 10 minutes to pellet
the cells. Supernatant of BALf was taken and stored at -
20°C for surfactant analysis and measurement of the
amount of alveolar serum protein.
Cell collection
Left and right lung, thoracic lymph nodes (TLN), and
spleen were collected, smashed and suspended in NaCl.
Cell suspensions were centrifuged at 400 g and 4°C for 10
minutes to pellet the cells. Red blood cells were lysed with
erythrocyte lysis buffer, whereafter the suspension was
washed with murine FACS buffer (MFB) (phosphate buff-
ered saline (PBS), 0.05% weight/volume (w/v) sodium
azide and 5% w/v bovine serum albumin (BSA)), centri-
fuged and resuspended in MFB. Cells were counted with a
Bürker-Turk cell counter (Erma, Tokyo, Japan).
Flow Cytometry
Pelleted cells (max 1*106 cells per well) were incubated
on ice with 2% volume/volume (v/v) normal rat serum
(NRS) in MFB for 15 minutes to prevent non-specific
binding of Fc-receptors with primary antibodies. Hereaf-
ter, cells were washed, centrifuged and surface-stained for
30 minutes at 4°C in the dark with the following primary
mouse anti rat antibodies: biotin conjugated CD5
(OX191), phycoerythrin (PE) labelled CD8 (OX82), fluo-
rescein-isothiocyanate (FITC) labelled CD4 (OX382),
CD45RA-PE (OX331), and HIS481. After centrifuging and
washing, primary staining of the HIS48 and OX-19-Biotin
antibody was revealed by secondary staining with respec-
tively goat anti mouse IgM, conjugated to PE
(STAR86PE1) and streptavidin RPE-Cy5 (phycoerythrin-
cychrome) (STAR891) for 30 minutes at 4°C in the dark.
Antibodies were obtained commercially from Serotec1
(Kidlington, United Kingdom) and BD2 (Franklin Lakes,
New Jersey, USA).
Cellular differentiation was calculated based on morphol-
ogy (Side SCatter (SSC) for granularity, Forward SCatter
(FSC) for size), autofluorescence and specific positive
antibody staining. Cells were identified as follows: Lym-
phocytes low FSC, low SSC, no autofluorescence, and
expressing either CD45RA+  (B-lymphocytes), CD5+  (T-
lymphocytes), CD5+CD4+  (helper T-lymphocytes), and
CD5+CD8+  (cytotoxic T-lymphocytes); neutrophils low
FSC, intermediate SSC and HIS48+; macrophages as high
SSC and FSC and autofluorescent [34].Respiratory Research 2008, 9:28 http://respiratory-research.com/content/9/1/28
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Data were acquired on a FACS Calibur flowcytometer
(BD, Franklin Lakes, New Jersey, USA) and were analyzed
using CellQuest (BD, Franklin Lakes, New Jersey, USA)
and FlowJo software (Tree Star, Ashland, Oregon, USA).
SA/LA ratio
Supernatant of BALf was centrifuged at 4°C for 15 min-
utes at 40.000 g to separate surface-active surfactant pellet
(large aggregate (LA)) from a non-surface active superna-
tant fraction (small aggregate (SA)). LA was resuspended
in 2 ml NaCl, whereafter the phosphorus concentration of
LA and SA was determined by phospholipid extraction,
followed by phosphorus analysis [35].
Protein concentration
The supernatant was further used to determine alveolar
protein concentration using the Bio-Rad protein assay
(Bio-Rad, Hercules, California, USA) using a Beckmann
DU 7400 photospectrometer with a wavelength set at 595
nm (Beckmann, Fullerton, California, USA) [36]. Bovine
serum albumin was used as standard.
Determination of matrix-metallo-proteinase activity
To determine the activity of MMP-2 and MMP-9, gelatin
zymography was performed on BALf of the left lung (n =
6 per group, randomly assigned). Zymography was con-
ducted on 10% SDS-polyacrylamide gels containing 1%
w/v porcine skin gelatin (Sigma-Aldrich, St. Louis, Mis-
souri, USA). The samples were 1:1 mixed with SDS-PAGE
sample buffer (0.25 M Tris HCl, pH 6.8, 2% w/v SDS, 20%
v/v glycerol, 0.01% v/v bromofenol blue), heated for 3
minutes at 55°C and subjected to standard electro-
phoretic analysis at room temperature using the protean II
system (Bio-Rad, Hercules, California, USA). After electro-
phoresis, gels were washed two times for 15 minutes with
2.5% Triton X-100 buffer to renature MMPs by removal of
SDS. Hereafter, gels were incubated with development
buffer (5 mM CaCl2, 50 mM Tris HCl, pH 8.8, 0.02% w/v
NaN3, aquadest) for 20 hours and proteins were fixated
for 15 minutes using 45% v/v methanol and 10% v/v ace-
tic acid. Gelatinolytic activity was visualized as clear zones
after staining with 0.1% w/v Coomassie Brilliant Blue R-
250 in 45% v/v methanol and 10% v/v acetic acid and
subsequent destaining in the same solution without
Coomassie Brilliant Blue. Gels were scanned (Kodak
image station 440 cf; Kodak, Rochester, New York, USA)
and quantified (Kodak image analysis software). A control
sample was used in all gels to be able to compare the var-
ious blots. After measuring the band intensity of all blots,
values were multiplied by a correction factor, determined
by the values of the control sample.
Histology
Histological assessment was performed in 3 animals per
group per time point. The heart and lungs were excised en
bloc, whereafter the lungs were fixated at a pressure of 10
cm H2O in 4% paraformaldehyde for 24 hours and
embedded in paraffin wax. Sections were cut and stained
with haematoxylin and eosin (HE). A histopathologist
(MdB), blinded for the treatment, performed histological
examination on the following parameters: intra-alveolar
and septal edema, hyaline membrane formation, inflam-
mation (classified as histiocytic, lymphocytic, granulo-
cytic, and mixed), fibrosis, atelectasis, intra-alveolar
hemorrhage, and overall classification. Each parameter
was ranked as mild/scattered, moderate/occasional, or
severe/frequent. Sections were overall classified as 1) nor-
mal, if no abnormalities were seen, 2) exsudative, if pul-
monary edema and/or hyaline membranes were present,
3) fibroproliferative, if activated fibroblasts and/or prolif-
erating alveolar type II cells were found, and 4) resolving,
if injury was on return to normal.
Slides were scored on a Leica DMLB light microscope and
photographes were taken using a Leica DC500 camera
(Leica Microsystems AG, Wetzlar, Germany).
Statistical analysis
The results in text, tables and figures are presented as
mean ± standard error of the mean (SEM). Data were ana-
lysed using SPSS version 11.1 statistical software (SPSS
Inc., Chicago, Illinois, USA). If an overall difference
between groups was found by the Kruskal-Wallis test,
Mann-Whitney U tests were performed for intergroup
comparison. Difference in mortality rate was assessed by
the Fisher's exact test. P values < 0.05 were considered to
be significant.
Results
Survival and weight loss
All sham-operated animals survived the experimental
period. LIRI resulted in a mortality rate of 25% (0/50 in
sham-operated animals versus 19/75 after LIRI, P  <
0.0001). Non-surviving LIRI animals died shortly after
weaning due to the development of pulmonary edema.
Surviving LIRI animals had lost more weight on day 3 as
compared to sham-operated rats (-34.91 ± 3.86 g versus -
21.10 ± 2.86 g, P = 0.01). From day 7 on these differences
had disappeared.
PaO2 & PaCO2
Arterial oxygenation was lower in LIRI animals than in
unoperated and sham-operated controls on day 1, 3, and
7 (Table 1). On day 30 and 90, these differences had dis-
appeared. An elevated PaCO2 was found 1 day after LIRI,
as compared to unoperated and sham-operated animals.
Static compliance of the left lung
LIRI had detrimental effects on both the Cmax and Vmax
of the left ischemic lung as compared to control lungsRespiratory Research 2008, 9:28 http://respiratory-research.com/content/9/1/28
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(Table 2). Up to 90 days after LIRI, Vmax and Cmax of the
left lung remained lower than in sham-operated and
unoperated rats.
Capillary permeability
The alveolar serum protein level of the ischemic left lung,
as parameter for capillary permeability, was increased 1
day after reperfusion as compared to controls (Table 3).
On day 3 the amount of alveolar serum protein in left
BALf of LIRI animals was still higher than in unoperated
rats. From day seven on, no differences were present.
Matrix metalloproteinase activity
MMP-2 is expressed constitutively in all animals (Figure 1
and 2). However, the total amount of pro- and active
MMP-2 and MMP-9 per microliter BALf is increased in
LIRI animals on day 1 (Figure 2) (recovered volume did
not differ between the groups). MMP activity per micro-
gram protein in the BALf, does not differ between the
groups (data not shown), which indicates that the
increased activity after LIRI must be due to elevated alveo-
lar serum proteins. After day 3, no differences were
demonstrable between the groups.
Surfactant small and large aggregates
While an increase in SA was found in the BALf of the left
lung of sham-operated animals on day 1, a higher level
was measured in LIRI lungs (Figure 3). After LIRI, an ele-
vated amount of SA was also found in the right lung on
day 1. The amount of LA in the left lung was decreased
from day 3 until day 30 following LIRI, whereafter the LA
level returned to normal on day 90.
Table 1: PaO2/FiO2 and PaCO2/FiO2 ratio, based on both lungs
Blood gas values Mean PaO2/FiO2 (SEM) [mm Hg] Mean PaCO2/FiO2 (SEM) [mm Hg]
Unoperated 562 (25) 45.4 (4.6)
Sham day 1 559 (17) 39.3 (2.3)
Sham day 3 520 (23) 40.8 (4.5)
Sham day 7 573 (17) 50.4 (7.8)
Sham day 30 561 (12) 41.5 (3.5)
Sham day 90 576 (21) 37.2 (4.0)
LIRI day 1 282 (41) US1L7–90 61.1 (6.1) US1L7–90
LIRI day 3 241 (38)US3L7–90 48.0 (4.8)
LIRI day 7 435 (48)US7L90 44.8 (2.2)
LIRI day 30 543 (22) 42.3 (2.0)
LIRI day 90 607 (14) 30.2 (2.4) UL1–30
U = P < 0.05 versus unoperated animals
Sx-y = P < 0.05 versus sham-operated animals from day x until day y
Lx-y = P < 0.05 versus LIRI animals from day x until day y
FiO2 = Fraction of inspired Oxygen; LIRI = Lung Ischemia-Reperfusion Injury; PaO2 = Arterial Oxygen pressure; PaCO2 = Arterial Carbon dioxide 
pressure; SEM = Standard-Error of the Mean
Table 2: Static compliance of the left lung, corrected for body weight
Left Lung Compliance Mean Vmax (SEM) [ml/kg] Mean Cmax (SEM) [(ml/kg)/cm H2O]
Unoperated 13.4 (0.48) 1.12 (0.10)
Sham day 1 15.9 (1.13) 1.32 (0.11)
Sham day 3 15.9 (0.81) U 1.26 (0.18)
Sham day 7 14.1 (1.21) 0.95 (0.04) S1
Sham day 30 12.3 (0.63) S1–3 1.00 (0.08) S1
Sham day 90 11.8 (0.58) S1–3 1.09 (0.06)
LIRI day 1 4.8 (0.59) US1L7 0.29 (0.05)US1L30–90
LIRI day 3 5.0 (0.68) US3L7 0.32 (0.05) US3L90
LIRI day 7 9.0 (1.51) US7 0.53 (0.12) US7
LIRI day 30 6.2 (0.75) US30 0.51 (0.06) US30
LIRI day 90 6.9 (1.04) US90 0.67 (0.11) US90
U = P < 0.05 versus unoperated animals
Sx-y = P < 0.05 versus sham-operated animals from day x until day y
Lx-y = P < 0.05 versus LIRI animals from day x until day y
Cmax = Maximal compliance of the expiration curve, corrected for body weight; LIRI = Lung Ischemia-Reperfusion Injury; SEM = Standard-Error of 
the Mean; Vmax = Maximal lung volume corrected for body weight at a pressure of 35 cm H2ORespiratory Research 2008, 9:28 http://respiratory-research.com/content/9/1/28
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Infiltrating cells
Neutrophils
Sham operation resulted in some infiltration of neu-
trophils in the first days after the operation, as demon-
strated by an elevated percentage in left and right BALf
and lung tissue (see additional file 1, Table 4A, 5A, 6A and
7A). However, after LIRI even more neutrophils were
measured in predominantly the left, but also the right
BALf (Figure 4A this manuscript; see additional file 1,
Table 4B and 5B) and lung tissue (Figure 4C this manu-
script; see additional file 1, Table 6B and 7B). Hereafter
the number of neutrophils gradually decreased, and could
not be measured anymore on days 30 and 90.
Macrophages
Macrophage occurrence followed similar kinetics in
sham-operated and ischemic lungs, but more macro-
phages were present on day 1 and 3 in ischemic lung tis-
sue and on day 3 and 7 in BALf (Figure 4B and 4D this
manuscript; see additional file 1, Table 4B and 6B). LIRI
also led to an increase in macrophages in the BALf of the
contralateral lung on day 3 and 7 as compared to sham
and unoperated animals (Figure 4B this manuscript; see
additional file 1, Table 5B). Although in sham-operated
and LIRI animals macrophages had returned to normal on
day 30 in left BALf, they were again elevated on day 90
(Figure 4B this manuscript, see additional file 1, Table
4B).
Lymphocytes
Sham operation did not result in infiltration of lym-
phocytes in BALf (Figure 5A–C this manuscript; see addi-
tional file 1, Table 4B). After LIRI, an infiltration of mainly
CD5+CD4+  and CD5+CD8+  and to a lesser extent
CD45RA+-lymphocytes occurred in mainly the left, but
also right BALf. Lymphocyte infiltration peaked on day 3,
with levels decreasing thereafter (Figure 5A–C this manu-
script; see additional file 1, Table 4B and 5B).
Table 3: Alveolar serum proteins of the left lung
Alveolar proteins Mean Proteins (SEM) [μg/ml]
Unoperated 226 (51)
Sham day 1 386 (131)
Sham day 3 323 (76)
Sham day 7 154 (51)
Sham day 30 151 (50)
Sham day 90 202 (65)
LIRI day 1 1,663 (202) US1L3–90
LIRI day 3 447 (75) UL7–90
LIRI day 7 168 (60)
LIRI day 30 79 (25)
LIRI day 90 74 (25)
U = P < 0.05 versus unoperated animals
Sx-y = P < 0.05 versus sham-operated animals from day x until day y
Lx-y = P < 0.05 versus LIRI animals from day x until day y
LIRI = Lung Ischemia-Reperfusion Injury; SEM = Standard-Error of the 
Mean.
MMP-2 and MMP-9 zymography Figure 1
MMP-2 and MMP-9 zymography. Pro MMP-9 was not measurable in any of the samples and active MMP-9 was detectable in the 
BALf of sham-operated and LIRI animals on day 1. Pro and active MMP-2 is expressed constitutively in all animals. BALf = Bron-
cho-Alveolar Lavage Fluid; LIRI = Lung Ischemia-Reperfusion Injury; MMP = Matrix MetalloProteinase.Respiratory Research 2008, 9:28 http://respiratory-research.com/content/9/1/28
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Although lymphocytes in right lung tissue of LIRI animals
followed the same kinetics as in sham-operated animals,
demonstrated by a decreased number on day 1 (Figure
5D–F this manuscript; see additional file 1, Table 7B),
more CD5+CD4+ and CD5+CD8+-cells were found in left
lung tissue on day 1 and 3 as compared to sham-operated
and unoperated animals (Figure 5D–E this manuscript;
see additional file 1, Table 6B). On day 1 also more
CD45RA+-cells were present in the left lung of LIRI ani-
mals (Figure 5F this manuscript; additional file 1, Table
6B). On day 90, the level of CD5+CD4+, CD5+CD8+, and
CD45RA+ lymphocytes in left lung tissue of LIRI animals
had decreased as compared to controls (Figure 5D–F this
manuscript; see additional file 1, Table 6B).
No differences were found between groups in percentage
or total number of cells within the spleen (data not
shown). However, more CD5+CD4+, and CD5+CD8+-cells
were measured in TLN on day 3 (Figure 6A–C this manu-
script; see additional file 1, Table 8B). Whereas
CD5+CD4+ and CD5+CD8+-cells remained higher in LIRI
animals than in unoperated animals up to day 90,
CD45RA+-cells had returned to preoperative values on day
90.
Histology
LIRI resulted in diffuse alveolar damage consisting of
severe intra-alveolar edema up to day 3, septal edema,
which was mild on day 1 and increased to moderate on
day 3, and intra-alveolar hemorrhages (Figure 7 this man-
uscript; see additional file 1, Table 9). The overall classifi-
cation of LIRI animals changed from exsudative on day 1
to proliferative from day 3 to day 90. Although no atel-
ectasis and fibrosis were seen on day 1 following LIRI,
MMP production measured in BALf by zymography Figure 2
MMP production measured in BALf by zymography. On day 1, significant more pro-, and active MMP-2 and active MMP-9 was 
found in the BALf of LIRI animals as compared to sham-operated and unoperated controls. BALf = Broncho-Alveolar Lavage 
Fluid; LIRI = Lung Ischemia-Reperfusion Injury; MMP = Matrix MetalloProteinase. U = P < 0.05 versus unoperated animals. Sx-y 
= P < 0.05 versus sham-operated animals from day x until day y. Lx-y = P < 0.05 versus LIRI animals from day x until day yRespiratory Research 2008, 9:28 http://respiratory-research.com/content/9/1/28
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mild fibrosis and mild to severe atelectasis were seen from
day 3 up to day 90 after LIRI (Figure 8 this manuscript; see
additional file 1, Table 9). Identification of infiltrating
cells confirmed the flowcytometry measurements. A mild
inflammatory pattern consisting of histiocytes was found
on day 3 and 7 in sham-operated animals. LIRI caused
moderate to severe inflammation, which changed from
mixed (granulocytic, lymphocytic, and histiocytic)
Total amount of SA and LA phospholipids in left and right BALf Figure 3
Total amount of SA and LA phospholipids in left and right BALf. SA and LA phospholipids (mg/kg body weight) were measured 
in left and right BALf of unoperated, sham-operated and LIRI animals on day 1, 3, 7, 30 and 90. Elevated levels of SA were found 
in both left and right BALf on day 1 and a decreased level of LA was measured up to day 30 in LIRI animals. BALf = Broncho-
Alveolar Lavage Fluid; LIRI = Lung Ischemia-Reperfusion Injury; SA = Small Aggregate; LA = Large Aggregate. U = P < 0.05 ver-
sus unoperated animals. Sx-y = P < 0.05 versus sham-operated animals from day x until day y. Lx-y = P < 0.05 versus LIRI animals 
from day x until day yRespiratory Research 2008, 9:28 http://respiratory-research.com/content/9/1/28
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inflammation on day 1 to a histiocytic and lymphocytic
pattern from day 3 to 90 (Figure 9 this manuscript; see
additional file 1, Table 10). No major differences between
unoperated, sham-operated and LIRI animals were found
in the right lung (data not shown).
Discussion
This study describes the effect of warm LIRI on a broad
spectrum of LIRI parameters, such as lung function, capil-
lary permeability, MMP production, surfactant conver-
sion, and histology on the short and long term after LIRI.
Furthermore, a detailed description of the subsets of leu-
kocytes and the time course of infiltration on both short
and long term after LIRI is given.
LIRI has been suggested to be a major risk factor for PAGF.
The clinical course of PAGF symptomatically resembles
the acute respiratory distress syndrome (ARDS) and can
be characterized by different stages, each with their spe-
cific clinical, histological and immunological changes
The number of inflammatory cells in BALf and lung tissue of the left (day 0–90) and right lung (day 0–7) Figure 4
The number of inflammatory cells in BALf and lung tissue of the left (day 0–90) and right lung (day 0–7). Shown are (A) neu-
trophils, and (B) macrophages in BALf; (C) neutrophils, and (D) macrophages in lung tissue. Day 0 represents the baseline value 
measured in unoperated animals. BALf = Broncho-Alveolar Lavage Fluid. U = P < 0.05 versus unoperated animals. Sx-y = P < 
0.05 versus sham-operated animals from day x until day y. Lx-y = P < 0.05 versus LIRI animals from day x until day yRespiratory Research 2008, 9:28 http://respiratory-research.com/content/9/1/28
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The number of inflammatory cells in BALf and lung tissue of the left (day 0–90) and right lung (day 0–7) Figure 5
The number of inflammatory cells in BALf and lung tissue of the left (day 0–90) and right lung (day 0–7). Shown are (A) helper 
T-lymphocytes (CD5+CD4+), (B) cytotoxic T-lymphocytes (CD5+CD8+), and (C) B-lymphocytes (CD45RA+) in BALf; (D) 
helper T-lymphocytes, (E) cytotoxic T-lymphocytes, and (F) B-lymphocytes in lung tissue. Day 0 represents the baseline value 
measured in unoperated animals. BALf = Broncho-Alveolar Lavage Fluid. U = P < 0.05 versus unoperated animals. Sx-y = P < 
0.05 versus sham-operated animals from day x until day y. Lx-y = P < 0.05 versus LIRI animals from day x until day yRespiratory Research 2008, 9:28 http://respiratory-research.com/content/9/1/28
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[37]. The acute, exsudative phase is featured by a sudden
onset of hypoxemia, decreased lung compliance,
increased pulmonary artery pressure, and development of
non-cardiogenic pulmonary edema [37,38]. Experimental
studies have shown that abnormalities in, and depletion
of pulmonary surfactant contribute to these symptoms of
LIRI [26-28,39-41]. Histological analysis of LIRI shows
diffuse alveolar damage with atelectasis, inflammation,
intra-alveolar hemorrhage, formation of hyaline mem-
branes and protein-rich edema [1,37]. Finally, production
of matrix-metalloproteinases (MMP) is thought to be
important in the acute phase of PAGF since MMPs
increase the microvascular permeability and thereby ena-
ble extravasation of inflammatory cells [42-45].
We found hypoxemia, impaired left lung compliance, a
mortality rate of 25% due to development of severe pul-
The number of inflammatory cells in TLN (day 0–90) Figure 6
The number of inflammatory cells in TLN (day 0–90). Shown 
are (A) helper T-lymphocytes (CD5+CD4+), (B) cytotoxic T-
lymphocytes (CD5+CD8+), and (C) B-lymphocytes 
(CD45RA+) in TLN. Day 0 represents the baseline value 
measured in unoperated animals. TLN = Thoracic Lymph 
Nodes; U = P < 0.05 versus unoperated animals. Sx-y = P < 
0.05 versus sham-operated animals from day x until day y. Lx-
y = P < 0.05 versus LIRI animals from day x until day y
Histological examples of alveolar edema (25*), septal edema  (100*) and intra-alveolar hemorrhage (40*) on HE slides Figure 7
Histological examples of alveolar edema (25*), septal edema 
(100*) and intra-alveolar hemorrhage (40*) on HE slides. LIRI 
caused alveolar and septal edema and alveolar hemorrhages, 
which were most severe on day 1 and 3 after LIRI and 
resolved thereafter. On day 7 brownish macrophages were 
found after clearance of erythrocytes in the alveolus. HE = 
Haematoxylin and Eosin staining; LIRI = Lung Ischemia-
Reperfusion Injury.Respiratory Research 2008, 9:28 http://respiratory-research.com/content/9/1/28
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monary edema, and an increase in SA subtype surfactant
as early effects of LIRI. Conversion of highly surface active
LA into poor surface active SA occurs shortly after reper-
fusion and is partly due to increased capillary permeabil-
ity, resulting in influx of serum proteins into the alveolus,
as confirmed in our study [28,46]. Serum proteins inhibit
surfactant in a dose-dependent manner by competing
with surfactant components at the alveolo-capillary bar-
rier [47]. HE slides confirmed extensive alveolar and sep-
tal edema, intra-alveolar bleeding, atelectasis and
Histological examples of atelectasis (10*) on HE slides Figure 8
Histological examples of atelectasis (10*) on HE slides. 
Severe atelectasis was demonstrated up to day 90 after LIRI. 
HE = Haematoxylin and Eosin staining; LIRI = Lung Ischemia-
Reperfusion Injury.
Histological examples of the inflammatory pattern of LIRI on  HE slides (100*) Figure 9
Histological examples of the inflammatory pattern of LIRI on 
HE slides (100*). Histological analysis confirms the flowcyto-
metric analysis with the presence of predominantly neu-
trophils on day 1, alveolar macrophages on day 3, and 
histiocytes on day 30 following LIRI. HE = Haematoxylin and 
Eosin staining; LIRI = Lung Ischemia-Reperfusion InjuryRespiratory Research 2008, 9:28 http://respiratory-research.com/content/9/1/28
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inflammation, which are all indicative of diffuse alveolar
damage. The increase in alveolar proteins and neutrophils
on day 1 occurred simultaneously with an increased MMP
activity. MMP-2 is usually constitutively expressed by
endothelial cells, vascular smooth muscle cells and
fibroblasts, fitting with the observation in our study of
high levels of both pro-, and active MMP-2 found in
unoperated animals [42-45,48]. Yano et al demonstrated
that LIRI resulted in MMP-9 induction, but not MMP-2
expression 24 hours after LIRI [45]. A higher concentra-
tion of MMP-9 was also found in lung edema fluid of
ARDS patients [49]. Nevertheless, we found that levels of
both pro- and active MMP-9 and MMP-2 per microliter
BALf are elevated 24 hours after LIRI, which correlates
well with the presence of neutrophils in left lung BALf.
Thus 120 minutes of warm ischemia resulted in our exper-
imental study in a mortality rate of 25%, hypoxemia, early
impaired left lung compliance, surfactant conversion, dif-
fuse alveolar damage on HE slides and MMP production,
which are all features of the exsudative phase of PAGF.
Human lung transplant patients surviving the acute phase
of LIRI may either recover from injury or enter a 'chronic'
fibroproliferative state, which develops within 4–7 days
after the onset of symptoms [37,38]. The progression
from an exsudative phase to a 'chronic' fibroproliferative
state within one week after LIRI is supported in our study
by the presence of fibroproliferative changes on HE slides
in the first week after LIRI and an increased number of
macrophages, which are important mediators in the regu-
lation of fibroblast function. Importantly, LIRI induced
progressive changes resulting in extensive pulmonary
injury up to 3 months after reperfusion. This is demon-
strated by a decreased number of lymphocytes found in
lung tissue on day 30 and 90, impaired left lung compli-
ance up to day 90, extensive atelectasis on HE slides, and
a decreased surfactant recycling and secreting capacity of
alveolar type II cells reflected by the decreased LA sur-
factant subtype [50]. Although extensive left pulmonary
injury was found on the long-term, hypoxemia was dem-
onstrated up to day 7. Thereafter, no differences in PaO2
were measured between LIRI animals and controls. This
discrepancy may be explained by the fact that PaO2 was
dependent on both lungs, so that the loss of left lung func-
tion was compensated by the right lung. Furthermore,
even though MMPs are important mediators of pulmo-
nary remodeling, no changes in activity on the long-term
were found. It is questionable however whether MMPs are
present in the BALf of severe atelectatic and fibrotic lungs.
Therefore, in future studies, measurement of MMP activity
should also be performed in homogenized lung tissue.
Thus, 120 minutes of warm ischemia in this model
induces injury comparable to PAGF and ARDS in clinical
lung transplantation on the short, but also on the long-
term. Nevertheless, this experimental model has several
shortcomings we wish to address. First of all, we used
warm ischemia to induce LIRI, whereas in the clinical set-
ting cold ischemic time is associated with PAGF. However,
it has been demonstrated that there are no major differ-
ences between short periods of warm and longer periods
of cold ischemia and warm ischemia has been used exten-
sively in IRI models of liver and kidney as an accelerated
model of clinically relevant cold IRI [15-19]. Another dis-
advantage is that a rather long period of 120 minutes
warm ischemia has been used. Shorter periods of warm
ischemia have been investigated in a pilot study to setup
our model (data not shown) and we found that 120 min-
utes of warm ischemia is necessary in our hands to induce
symptoms comparable to PAGF. This finding is supported
by a clinical study by Thabut et al, which shows that the
relationship between cold graft ischemic time and survival
appears to be of cubic form with a cutoff value of 330
minutes [3]. Thereafter short-term mortality increases rap-
idly mainly due to development of PAGF [3].
Another goal of this study was to describe leukocyte kinet-
ics following LIRI. The immunologic effects of LIRI have
only been studied up to hours after reperfusion, whereas
we investigated leukocyte kinetics after LIRI up to 90 days
post-reperfusion. Several studies have shown that macro-
phages are activated during ischemia, followed by the
recruitment of neutrophils within hours after the start of
reperfusion [16,19,20,22,24,25,29,51,52]. We now add
that neutrophil infiltration lasted for 3 days after reper-
fusion, thereby strengthening the theory that neutrophils
are important in perpetuating LIRI. The extended presence
of neutrophils after LIRI may be also explained by the fact
that phagocytes are important elements of the repair proc-
ess after LIRI by clearing apoptotic cells and necrotic
debris [29]. Nevertheless, since ischemia-reperfusion
injury still develops in neutropenic models, it is question-
able whether neutrophils are pivotal in LIRI [21,32].
In this regard, other studies suggest an early role for T cells
as important mediators of ischemia induced injury. An
infiltration of CD4+-T-cells occurred in these studies from
1 until 12 hours after reperfusion and disappeared hereaf-
ter [16,19,20,51], whereas we found elevated numbers of
mainly CD5+CD4+ and CD5+CD8+ T-lymphocytes 3 and 7
days after reperfusion in the left lung and TLN. Infiltration
and activation of T cells has been classically attributed to
the presence of antigen; our findings in an autologous set-
ting may be explained by different mechanisms. First, LIRI
induced upregulation of adhesion molecules may attract
T cells, such as effector and memory T-cells, which are able
to proliferate in an antigen independent fashion by
cytokines produced locally (bystander effect), in contrast
with naïve T-cells which require antigen presentation by
antigen presenting cells [53]. Moreover, antigen specific T-Respiratory Research 2008, 9:28 http://respiratory-research.com/content/9/1/28
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cells may be attracted by released self-antigens [54,55].
Myosin, heat shock proteins and type V collagen, which is
released after LIRI in BALf comparable to the level
observed in allografted lungs, have been shown to be
capable of inducing a T-helper-cell reaction within days
after reperfusion [54,55]. The latter is supported by the
finding of Waddell and colleagues, who demonstrated
upregulation of major histocompatibility II complex after
LIRI [56]. Finally, the elevated levels of CD5+CD4+ and
CD5+CD8+ may be explained by their possible role in the
pathogenesis of lung fibrosis, which is also supported by
the presence of macrophages in the BALf and lung paren-
chyma of ischemic animals 3, 7, and 90 days after reper-
fusion, since they are also thought to be important
mediators in the regulation of fibroblast function
[37,38,57,58].
Our study furthermore demonstrates an immunosuppres-
sive effect of operation, as measured by the decreased
number of lymphocytes in lung tissue on day 1. Although
it is very well known that major surgery may cause a short-
lasting decrease in blood circulating lymphocytes [59], we
now additionally report that thoracotomy causes a one
day decrease in the number of lymphocyte subset in lung
parenchyma, while the number of lymphocytes in the
BALf of sham-operated animals is close to normal. The
immunosuppressive effect of surgery may be due to
reduced T-cell proliferation and reduced secretion of
interleukin-2 (IL-2), IL-4, and gamma interferon by T-
lymphocytes, which may be the effect of inhibitory factors
secreted by mononuclear phagocytic cells as a result of
injury [60]. Moreover, altered migration of memory and
activated effector T cells to injury sites may have also con-
tributed to the decreased level of measured cells [61].
Finally, another interesting point arising from this study is
the effect of left LIRI on right-sided pulmonary injury.
While no major changes were seen on HE slides of the
right lung, the inflammatory profile of the right BALf
resembled that of the left, although it was less severe. Also,
an increased amount of SA was measured in these parts of
the lung, demonstrating that the right lung has sustained
injury. Since the right lung did not sustain ischemia,
induction of systemic components, similar to that seen
after mesenteric artery ischemia, may have caused right
lung injury. In this regard, induction of high-mobility
group-1 protein, a downstream proinflammatory
cytokine produced by necrotic cells [62,63], and produc-
tion of uric acid could explain this phenomenon [64].
Furthermore, activated neutrophils lose their ability to
deform, so that they might have plugged the capillaries of
the right lung and may have subsequently caused lung
injury [65]. However, LIRI of the left lung did not result in
long-term damage in the right lung.
Conclusion
The short and long-term changes after LIRI in this model
resemble those found in both PAGF and ARDS after clini-
cal lung transplantation. Thus LIRI seems a major risk fac-
tor for PAGF in the absence of other influencing factors,
such as alloimmunity. Importantly, LIRI resulted in pro-
gressive deterioration of lung function and architecture,
leading to extensive immunopathological and functional
abnormalities up to 3 months after reperfusion. Immuno-
logically, LIRI caused neutrophil infiltration early after
reperfusion, followed by T lymphocytes and macro-
phages. The non-ischemic lung also showed signs of
inflammation on the short-term, but to a lesser extend,
and long-term changes were not found in the right lung.
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